MilliporeSigma builds on core offerings as it divests CDMO business

Merck KGaA says its life science business, which operates as MilliporeSigma in the U.S. and Canada, remains focused on supporting pharma, biotech, and CDMO customers.

It’s been a busy few weeks for Merck KGaA’s life science business, operating in the United States and Canada as MilliporeSigma. On Nov. 3, Germany’s Merck KGaA announced the divestiture of five U.S. contract development and manufacturing organization (CDMO) sites to Lonza. On Monday, the company agreed to acquire Massachusetts-based Rapid Micro Biosystems, which automates microbial quality-control testing in pharmaceutical manufacturing.

They are the latest moves for the supplier of life science products and services, which says it remains focused on investments in capabilities and technologies that will serve to strengthen its partnerships with pharmaceutical, biotechnology, and CDMO customers. 

At MilliporeSigma’s 2026 Life Science Innovation Summit, held Tuesday in Burlington, Massachusetts, the company laid out its strategy for providing a “more concentrated” life science portfolio of consumables, technologies, and services used across biopharmaceutical development and manufacturing.     

“We are investing and we continue to invest,” Jean-Charles Wirth, CEO of MilliporeSigma and a member of the executive board of Merck KGaA, told the audience, emphasizing that artificial intelligence (AI), digitalization, and sustainability “run through everything we do” shaping how the company develops, designs, and enables scientific innovation.     

Wirth made the case that biopharma customers need partners “who can stand with them across the full value chain of their journey, from early research to development to manufacturing.” He provided some examples of the company’s partners including a memorandum of understanding signed in September 2025 with Siemens, extending their strategic partnership to accelerate digital transformation in the life science industry.

The agreement, the first joint use of technology acquired by Siemens as part of the Dotmatics acquisition completed in July 2025, is focused on providing integrated software solutions, systems, and consumables that leverage AI, automation, and data.

Wirth said the purpose of the Siemens partnership is to “connect digital workflows from early drug discovery all the way to manufacturing” and has resulted in the recent launch of SYNTHIA Agentic AI,  providing scientists with natural-language access to retrosynthesis, reagent, and safety information within compatible AI environments.

MilliporeSigma is also continuing to invest in its internal infrastructure.

Last month, the company opened a $335 million bioprocessing production center in Daejeon, South Korea — its largest life science investment in Asia-Pacific to date — with integrated digital systems designed to support automated data capture and end-to-end batch traceability. The facility expands regional manufacturing capacity for materials used in biologics development and production.

The South Korea investment is part of MilliporeSigma’s in-region-for-region strategy, which aims to bring manufacturing and services closer to customers.

In August, it announced an expansion of its BioReliance biosafety testing laboratory in Singapore to add cell line characterization and Good Manufacturing Practice (GMP) next-generation sequencing capabilities. The expanded laboratory will be the first BioReliance facility in Asia-Pacific to offer both services, according to the company.

In July, MilliporeSigma opened a $29 million BioReliance testing facility in Darmstadt, Germany, expanding its European capabilities for commercial drug substance and drug product release testing. The facility will provide commercial release testing and GMP-compliant stability studies for biologics, including monoclonal antibodies and cell therapies. The site expands its BioReliance testing network and supports customers from drug development through commercial manufacturing.

Acquisitions part of growth strategy

Monday’s announcement about the Rapid Micro Biosystems acquisition is the most recent example of Merck KGaA’s continued buying spree, as it looks to scale capabilities and leverage its market position as an integrated science and technology company.

In June 2026, Merck KGaA agreed to acquire Minneapolis-based life science tools, analytical technologies, and consumables company Bio-Techne for an enterprise value of $11.3 billion. The planned acquisition of Bio-Techne will add complementary strengths across research, bioprocessing, and advanced therapeutics, boosting its offerings in next-generation biology, according to the company.

Last year, MilliporeSigma announced it was purchasing the Belgium-based chromatography business of JSR Life Sciences, a provider of contract development and manufacturing, preclinical and translational clinical research, and bioprocessing solutions. The acquisition is meant to expand the company’s downstream processing portfolio with advanced Protein A chromatography capabilities, supporting more efficient and scalable production of biopharma therapies, including monoclonal antibodies.

Protein A chromatography is a critical step in purifying monoclonal antibodies and therapeutic proteins used in treatments for cancer, autoimmune diseases, and infectious conditions. The technology is designed to improve product purity, safety, and manufacturing efficiency.

“We discover all these new medicines, but we have to get better at making them and more efficient,” said Chief Technology Officer Karen Madden at MilliporeSigma’s Tuesday summit.  

About the Author

Greg Slabodkin

Editor in Chief

As Editor in Chief, Greg oversees all aspects of planning, managing, and producing the content for Pharma Manufacturing’s website and digital products, as well as the daily operations of its editorial team.

For more than 20 years, Greg has covered the healthcare, life sciences, and medical device industries for several trade publications. He is the recipient of a Post-Newsweek Business Information Editorial Excellence Award for his news reporting and a Gold Award for Best Case Study from the American Society of Healthcare Publication Editors. In addition, Greg is a Healthcare Fellow from the Society for Advancing Business Editing and Writing.

When not covering the pharma manufacturing industry, he is an avid Buffalo Bills football and Buffalo Sabres hockey fan, likes to kayak, and plays guitar.

Sign up for our eNewsletters
Get the latest news and updates